MAPT and Alzheimer disease: Additionally, in patients with early clinical AD with age below 75 years, a predominant amyloid phenotype is most evident in male APOEɛ4 homozygotes, whereas female APOEɛ4 noncarriers demonstrate a predominantly tau phenotype [[66], [67], [68]].